Tarsus Pharmaceuticals (TARS) Projected to Announce Quarterly Earnings on Thursday

Tarsus Pharmaceuticals (NASDAQ:TARS) will likely be posting its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect Tarsus Pharmaceuticals to post earnings of ($0.1918) per share and revenue of $169.6770 million for the quarter. Parties may visit the the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 4:30 PM ET.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its quarterly earnings data on Wednesday, May 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.24. The business had revenue of $162.05 million for the quarter, compared to analysts’ expectations of $149.60 million. Tarsus Pharmaceuticals had a negative return on equity of 14.19% and a negative net margin of 9.02%. On average, analysts expect Tarsus Pharmaceuticals to post $-1 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Tarsus Pharmaceuticals Stock Performance

Shares of NASDAQ TARS opened at $61.11 on Wednesday. The firm has a market capitalization of $2.63 billion, a price-to-earnings ratio of -53.61 and a beta of 0.53. Tarsus Pharmaceuticals has a one year low of $40.55 and a one year high of $85.25. The business has a fifty day simple moving average of $61.15 and a 200 day simple moving average of $65.07. The company has a current ratio of 3.74, a quick ratio of 3.71 and a debt-to-equity ratio of 0.21.

Insider Buying and Selling

In other Tarsus Pharmaceuticals news, Director William J. Phd Link sold 12,500 shares of the company’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $62.12, for a total value of $776,500.00. Following the sale, the director directly owned 106,786 shares in the company, valued at $6,633,546.32. This represents a 10.48% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Katherine Goodrich sold 2,954 shares of the company’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $62.08, for a total value of $183,384.32. Following the completion of the sale, the director owned 2,233 shares in the company, valued at $138,624.64. This trade represents a 56.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 39,850 shares of company stock worth $2,452,821 in the last quarter. Corporate insiders own 9.64% of the company’s stock.

Institutional Trading of Tarsus Pharmaceuticals

Several large investors have recently added to or reduced their stakes in TARS. Invesco Ltd. raised its stake in shares of Tarsus Pharmaceuticals by 8.0% in the fourth quarter. Invesco Ltd. now owns 1,012,357 shares of the company’s stock valued at $82,892,000 after acquiring an additional 75,351 shares during the last quarter. Mackenzie Financial Corp bought a new stake in shares of Tarsus Pharmaceuticals during the fourth quarter worth $202,000. XTX Topco Ltd increased its stake in shares of Tarsus Pharmaceuticals by 270.3% in the fourth quarter. XTX Topco Ltd now owns 18,410 shares of the company’s stock valued at $1,507,000 after buying an additional 13,438 shares in the last quarter. Squadron Capital Management LLC acquired a new position in Tarsus Pharmaceuticals during the 4th quarter worth about $6,550,000. Finally, Tudor Investment Corp ET AL bought a new stake in Tarsus Pharmaceuticals during the 4th quarter worth about $1,859,000. 90.01% of the stock is owned by institutional investors.

Analyst Ratings Changes

TARS has been the topic of several analyst reports. Oppenheimer began coverage on shares of Tarsus Pharmaceuticals in a report on Friday, April 24th. They issued an “outperform” rating and a $98.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and set a $88.00 price objective on shares of Tarsus Pharmaceuticals in a report on Thursday, July 9th. Wall Street Zen lowered shares of Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Guggenheim lowered their target price on shares of Tarsus Pharmaceuticals from $90.00 to $89.00 and set a “buy” rating on the stock in a research note on Tuesday, July 21st. Finally, Mizuho dropped their price target on shares of Tarsus Pharmaceuticals from $100.00 to $98.00 and set an “outperform” rating for the company in a research report on Friday, July 31st. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $90.17.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a clinical?stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro?effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early?stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.